Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVX01 in healthy adults
NCT06337643Phase 1Active, not recruiting
- Sponsor
- Matrivax
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MVX01 in pneumococcal disease (5 arms), sponsored by Matrivax. Primary endpoints: Incidence of immediate reactogenicity adverse events, Incidence of solicited reactogenicity events at 7 days and 5 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
MVX01
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06337643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337643.